替比夫定治疗失代偿期乙肝肝硬化2年随访观察(2)
 |
| 第1页 |
参见附件。
[2] Leung N，Peng CY，Hann HW，et al.Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B:a randomized international study of entecavir versus adefovir.Hepatology，2009，49(1):72-79.
[3] Gisbert JP，Chaparro M，Esteve M.Review article:prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease.Aliment Pharmacol Ther，2011，33(6):619-633.
[4] 中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南.中华肝脏病杂志，2005，13:881-891.
[5] Papatheodoridis GV，Manolakopoulos S，Dusheiko G，et al.Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.Lancet Infect Dis，2008，8:167-178.
[6] 陈从新，刘波，郭顺明，等.拉米夫定治疗乙型肝炎肝硬化的临床观察.胃肠病学和肝病学杂志，2007，16(2):150-151.
[7] Amarapurkar DN.Telbivudine:Anewtreatment for chronic hepatitis B.World J Gastroenterol，2007，(13):6150-6155.
[8] Tacke F，Trautwein C.Hepatitis B goes globe:Telbivudine as a new treatment option.Hepatology，2008，47(5):1786-1787.
[9] Hou J，Yin YK，Xu D，et al.Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B:Results at 1 year of a randomized，double-blind trial.Hepatology，2008，47(2):447-454.
[10] Ching-Lung Lai，Edward Gane，Yun-Fan Liaw，et al.Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B.N Engl J Med，2008，358:1517-1518.
您现在查看是摘要介绍页，详见PDF附件。